Table 1.
Patient characteristics
| On treatment (N = 106)a | Surviving < 5 years (N = 77) | Surviving ≥ 5 years (N = 121) | Total (N = 304) | P valueb | |
|---|---|---|---|---|---|
| Age at diagnosis, years | < 0.001c | ||||
| N | 106 | 76 | 121 | 303 | |
| Mean (SD) | 41.54 (16.06) | 40.55 (17.04) | 30.39 (11.61) | 36.84 (15.59) | |
| Median | 40.00 | 36.50 | 29.00 | 34.00 | |
| Range | (19.00–80.00) | (18.00–79.00) | (6.00–72.00) | (6.00–80.00) | |
| Years from diagnosis to first visit | < 0.001c | ||||
| N | 106 | 77 | 121 | 304 | |
| Mean (SD) | 1.35 (3.06) | 2.13 (1.54) | 16.35 (8.87) | 7.51 (9.32) | |
| Median | 0.10 | 1.97 | 14.47 | 3.55 | |
| Range | (0.00–19.47) | (0.00–4.90) | (5.08–47.98) | (0.00–47.98) | |
| Sex | 0.172d | ||||
| Male | 57 (53.8%) | 36 (46.8%) | 50 (41.3%) | 143 (47.0%) | |
| Female | 49 (46.2%) | 41 (53.2%) | 71 (58.7%) | 161 (53.0%) | |
| Race | 0.022d | ||||
| White | 66 (62.3%) | 55 (71.4%) | 98 (81.0%) | 219 (72.0%) | |
| Non-White | 29 (27.4%) | 16 (20.8%) | 20 (16.5%) | 65 (21.4%) | |
| Unknown | 11 (10.4%) | 6 (7.8%) | 3 (2.5%) | 20 (6.6%) | |
| Ethnicity | 0.024d | ||||
| Hispanic or Latino | 4 (3.8%) | 3 (3.9%) | 4 (3.3%) | 11 (3.6%) | |
| Not Hispanic or Latino | 90 (84.9%) | 68 (88.3%) | 116 (95.9%) | 274 (90.1%) | |
| Unknown | 12 (11.3%) | 6 (7.8%) | 1 (0.8%) | 19 (6.3%) | |
| Charlson Score | 0.466c | ||||
| N | 106 | 77 | 121 | 304 | |
| Mean (SD) | 2.46 (1.34) | 2.64 (1.66) | 2.27 (0.87) | 2.43 (1.28) | |
| Median | 2.00 | 2.00 | 2.00 | 2.00 | |
| Range | (2.00–9.00) | (2.00–9.00) | (2.00–8.00) | (2.00–9.00) | |
| HL subtype | 0.370d | ||||
| Classical | 96 (90.6%) | 66 (85.7%) | 100 (82.6%) | 262 (86.2%) | |
| Nodular Lymphocyte predominant | 9 (8.5%) | 9 (11.7%) | 15 (12.4%) | 33 (10.9%) | |
| Gray zone | 0 (0.0%) | 1 (1.3%) | 0 (0.0%) | 1 (0.3%) | |
| Other | 0 (0.0%) | 0 (0.0%) | 1 (0.8%) | 1 (0.3%) | |
| Unknown | 1 (0.9%) | 1 (1.3%) | 5 (4.1%) | 7 (2.3%) | |
| Stage | 0.020d | ||||
| I | 6 (5.7%) | 10 (13.0%) | 18 (14.9%) | 34 (11.2%) | |
| II | 46 (43.4%) | 30 (39.0%) | 59 (48.8%) | 135 (44.4%) | |
| III | 24 (22.6%) | 23 (29.9%) | 32 (26.4%) | 79 (26.0%) | |
| IV | 28 (26.4%) | 12 (15.6%) | 10 (8.3%) | 50 (16.4%) | |
| Unknown | 2 (1.9%) | 2 (2.6%) | 2 (1.7%) | 6 (2.0%) | |
| Risk strata | 0.002d | ||||
| Early, favorable | 13 (12.3%) | 18 (23.4%) | 46 (38.0%) | 77 (25.3%) | |
| Early, unfavorable | 39 (36.8%) | 22 (28.6%) | 31 (25.6%) | 92 (30.3%) | |
| Advanced | 52 (49.1%) | 35 (45.5%) | 42 (34.7%) | 129 (42.4%) | |
| Unknown | 2 (1.9%) | 2 (2.6%) | 2 (1.7%) | 6 (2.0%) |
aA total of 95 patients on treatment were surviving less than 5 years, whereas 11 survived 5 or more years
bPatients with “unknown” status were excluded when calculating P values
cKruskal-Wallis test
dChi-square or Fisher’s exact test